Puget Technologies (PUGE) revealed its subsidiary, Cannabis Biotech, has entered into an agreement with a patent attorney as it launches its product research to develop a transmucosal system for the delivery of medical marijuana. Cannabis Biotech is developing a platform with the ability to deliver a reliable, standard dose of medicine. The transmucosal platform is an effective means to introduce treatments across the mucous membrane and is a well-established and accepted system of administration.
As previously announced, Cannabis Biotech is focusing on technologies whereby medical marijuana can be effectively administered through the transmucosal platform. This project is part of a larger effort to develop a wider variety of delivery methods to serve a growing, diverse patient base and is targeted towards those who desire the benefits of medical marijuana but do not want the harmful effects or stigma of smoking it.